Akkermansia muciniphila: a potential candidate for ameliorating metabolic diseases

Front Immunol. 2024 Mar 20:15:1370658. doi: 10.3389/fimmu.2024.1370658. eCollection 2024.

Abstract

Metabolic diseases are comprehensive disease based on obesity. Numerous cumulative studies have shown a certain correlation between the fluctuating abundance of Akkermansia muciniphila and the occurrence of metabolic diseases. A. muciniphila, a potential probiotic candidate colonized in the human intestinal mucus layer, and its derivatives have various physiological functions, including treating metabolic disorders and maintaining human health. This review systematically explicates the abundance change rules of A. muciniphila in metabolic diseases. It also details the high efficacy and specific molecules mechanism of A. muciniphila and its derivatives in treating obesity, type 2 diabetes mellitus, cardiovascular disease, and non-alcoholic fatty liver disease.

Keywords: Akkermansia muciniphila; gut microbiota; health; metabolic diseases; obesity.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Akkermansia
  • Diabetes Mellitus, Type 2*
  • Humans
  • Intestines
  • Obesity
  • Verrucomicrobia / metabolism

Supplementary concepts

  • Akkermansia muciniphila

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was funded by “Blueberry Pomace-Akkermansia muciniphila Synbiotics Regulatory Effects on Intestinal Microbiota” Fundamental Research Fund Project of Central Universities 2662019QD037 and “Agricultural Product Processing and Comprehensive Utilization” Team 1 Hubei Provincial Innovation Team Project (2021-2025)0120210150.